Friday, April 21, 2017

Epilepsy Patients are the New Focus of, Inc.’s (CIIX) CBD Health Products

In China, there are close to 10 million epilepsy patients, the Chinese Overseas Medical Advisory Service Center estimates. There is no cure in the country, although risky surgery is sometimes performed in the U.S., where there are over three million people living with epilepsy. Many patients rely on Chinese herbs for temporary control. However,’s (OTCQB: CIIX) current development plan includes making cannabidiol (CBD) products available online for people with epilepsy and Alzheimer’s disease. Its online store ( and Yelp-style mobile application are helping to serve Chinese-speaking consumers around the world, and investors as well, with a reach into the $202 million U.S. CBD industry (based on 2015 consumer sales), which is expected to exceed $2 billion by 2020.

Cannabis was used as a medicinal substance in China as early as 2700 BCE, and it was later used across India and the Middle East. Epilepsy patients were treated with cannabis as early as the 11th century. This application was studied in Europe in the 19th century, and research into the medical use of cannabis compounds took place throughout the 1930s and 1940s. Progress was hindered in 1970 as the U.S. Controlled Substances Act prohibited the production and use of any cannabis product. Today, cannabis-based products are gaining ground, and CIIX is paying close attention to the market.

A United Press International (UPI) report in December 2016 ( cited two clinical trials that found cannabidiol reduced the frequency of seizures in adults and children. In these studies, CBD was used in patients with Lennox-Gastaut syndrome and Dravet syndrome, which are rare, hard-to-treat forms of epilepsy. University of Alabama researchers found that CBD does reduce the frequency and severity of seizures, but not all patients exhibited the same benefits. Research has also indicated that CBD could interact with anti-seizure medications, causing decreases in liver function and sedation. Researchers also weren’t sure if mild to moderate side effects such as decreased appetite, sleepiness, vomiting, or diarrhea were associated with CBD.

Nonetheless, the popularity of CBD and cannabis-based products is adding fuel to the fire, and CIIX isn’t holding back either. It’s investing in enterprises focused on research and development. These include businesses studying CBD’s impact on epilepsy. Parents and caretakers have not been waiting for approval of cannabis products or traditional drugs to be approved by the U.S. Food and Drug Administration. Many have already obtained medical cannabis and seen positive results. Even the American Epilepsy Society has taken a stance, referencing anecdotal reports on the use of marijuana derivative cannabidiol in patients with treatment-resistant seizures ( It has called on both government and private funders to support research, so there’s more scientific data on the effectiveness of CBD as an epilepsy treatment.

Cannabidiol is gaining ground in the North American market. Legal in 50 states, it’s considered a food nutrient and is exported to China and over 40 other countries.

For more information, visit the company’s website at

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at

The Quality Stocks Daily Blog

The Quality Stocks Daily Videos

The Quality Stocks “Ones to Watch”

Please see disclaimer on the QualityStocks website:

No comments: